Multi-omics approaches to disease
Open accessThe DOI matches its Crossref record; 185 of the 186 references it cites were found in a registry or an index; 78 of the 108 sources its claims cite were checked for support.
Abstract
High-throughput technologies have revolutionized medical research. The advent of genotyping arrays enabled large-scale genome-wide association studies and methods for examining global transcript levels, which gave rise to the field of "integrative genetics". Other omics technologies, such as proteomics and metabolomics, are now often incorporated into the everyday methodology of biological researchers. In this review, we provide an overview of such omics technologies and focus on methods for their integration across multiple omics layers. As compared to studies of a single omics type, multi-omics offers the opportunity to understand the flow of information that underlies disease.
Overview
CoChat Summary
TL;DR
This review surveys omics technologies and argues that integrating multiple omics layers (“multi-omics”) can reveal the flow of information from genetic, environmental, or developmental causes to disease consequences better than single-omics studies. It organizes integrative approaches into genome-first, phenotype-first, and environment-first frameworks and discusses design, statistical, and translational challenges.
Key findings
- Single-omics analyses are mostly correlative; multi-omics integration is motivated by observations that GWAS loci explain only a fraction of heritability, common diseases often involve regulatory variation, and the same variants can yield different outcomes depending on environment and genetic background.
- Genome-first example: at the FTO obesity locus, chromatin maps across 127 cell types narrowed the region to an adipose-specific enhancer; IRX3 and IRX5 expression correlated with risk haplotype across 20 risk-allele and 18 non-risk-allele carriers, and CRISPR-Cas9 editing of rs1421085 implicated a single nucleotide variant disrupting ARID5B binding.
- Phenotype-first examples: in Alzheimer’s disease, profiling seven epigenetic modifications found AD-associated genetic variants enriched in immune-related enhancers but not promoters or neuronal-function enhancers; in cardiac arrhythmia, immunoprecipitation of five long QT proteins identified 584 co-precipitated proteins, with 12 genes overlapping 35 GWAS loci.
- Environment-first and population examples: 25 diets in over 800 mice showed macronutrient ratio effects on cardiometabolic health; about 100 inbred mouse strains were used to study high-fat/high-sucrose diet; 800 individuals were analyzed for personalized glycemic prediction; reference resources include METSIM (~10,000 Finnish men aged 45–65), MuTher (several hundred female twins), and UK Biobank (500,000 people).
Methods
- Narrative review, not a primary study; it describes genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics technologies and their application to human disease.
- No primary data or sample collection; evidence comes from cited published studies and consortia, including Roadmap Epigenomics, GTEx, ENCODE, UK Biobank, MuTher, and METSIM.
- Synthesis organizes multi-omics integration into genome-first, phenotype-first, and environment-first approaches and discusses correlation/co-mapping, mediation and conditional analysis, network modeling, ID conversion, and future directions.
Limitations
- Paper-stated: human omics studies face confounding (e.g., diet, lifestyle), limited sample sizes/power, batch effects, lack of agreed gold-standard pipelines, and difficulty distinguishing causal from reactive changes; animal models have limitations including single genetic backgrounds and incomplete recapitulation of human complex disease.
- Paper-stated: standardization across studies is difficult (e.g., RNA-Seq comparability depends on genome version, annotation, and quantification tools), and coordinated consortia are needed for multi-scale data generation, analysis, and translation.
- Evident: as a review, it presents no new empirical results, does not perform a systematic search or meta-analysis, and its examples are selected to illustrate concepts rather than to quantify effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Usage of omics applications to prioritize GWAS variants. Locus zoom plot for a complex GWAS locus shows several candidate genes could be causal. Heatmap using various omics approaches for evidence supporting or refuting candidate causal genes. Beyond literature queries for candidates, various omics technologies and databases can be used to identify causal genes, including: searching for expression in relevant tissues [173–175], summary data-based Mendelian randomization (SMR) [176], mediation analysis [177], conditional analysis [23], correlation analyses, searching for overlapping pQTLs [178, 179], and/or implementing epigenetic data to narrow candidates (discussed for FTO locus [16])](https://figures.cochat.ai/paper-figures/8dfaf7d842a04d1d8dbe1adf52822946/multi-omics-approaches-to-disease-figure-2.jpg)
![Fig. 3 Genome first approach at FTO GWAS locus. Claussnitzer et al [16] combined genomics, epigenomics, transcriptomics, and phylogenetic analysis to identify the functional element, the causative SNP, and the downstream genes mediating the genetic effect at the FTO locus in obesity. Circles represent genes in the locus and yellow circles represent genes implicated by the respective omics data. a Genomics: the FTO locus, containing several genes (circles), harbors the most significant obesity-associated haplotype in humans. SNPs that are in linkage disequilibrium with the risk allele are color coded—blue represents the non-risk (normal) haplotype and red the risk haplotype. b Epigenomics: publically available epigenomic maps and functional assays were used to narrow down the original associated region to 10 kb containing an adipose-specific enhancer. Chromatin capturing (Hi-C) was used to identify genes interacting with this enhancer. c Transcriptomics: this technique was used to identify which of the candidate genes are differentially expressed between the risk and normal haplotypes, identifying IRX3 and IRX5 as the likely downstream targets. In addition, conservation analysis suggested that rs1421085 (SNP that disrupts an ARID5B binding motif) is the causative SNP at the FTO locus. CRISPR-Cas9 editing of rs1421085 from background (TT) to risk allele (CC) was sufficient to explain the observed differences in expression of IRX3 and IRX5. d Functional mechanism: correlation and enrichment analysis were then used to identify potentially altered pathways that were then confirmed by in vitro and in vivo studies](https://figures.cochat.ai/paper-figures/db49d73e526542eb82eb53037ce106aa/multi-omics-approaches-to-disease-figure-3.jpg)
![Fig. 4 The flow of biologic information from liver DNA methylation to liver transcripts, proteins, metabolites, and clinical traits. A panel of 90 different inbred strains of mice were examined for DNA methylation levels in liver using bisulfite sequencing. CpGs with hypervariable methylation were then tested for association with clinical traits such as a obesity and diabetes, b liver metabolite levels, c liver protein levels, and d liver transcript levels. Each dot is a significant association at the corresponding Bonferroni thresholds across CpGs with the clinical traits and metabolite, protein, and transcript levels in liver. The genomic positions of hypervariable CpGs are plotted on the x-axis and the positions of genes encoding the proteins or transcripts are plotted on the y-axis. The positions of clinical traits and metabolites on the y-axis are arbitrary. The diagonal line of dots observed to be associated with methylation in the protein and transcript data represent local eQTL and pQTL. The vertical lines represent “hotspots” where many proteins or transcripts are associated with CpG methylation at a particular locus. Figure taken with permission from [180], Elsevier](https://figures.cochat.ai/paper-figures/57fe2a5e27a9419f9625d700545351a0/multi-omics-approaches-to-disease-figure-4.jpg)
Verification
Claims the paper makes
35 Valid · 11 Not valid · 16 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, the loci that have been identified so far generally explain only a fraction of the heritable component for specific diseases.”
§ Multi-omics approaches to disease > Introduction
What the sources say
- Could not verifycites [1] LaFramboise T. Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res. 2009;37:4181–93. sourceExperimental — accuracy not yet measured
The Introduction and the GWAS subsection discuss identifying variants associated with disease, but neither assesses how much disease heritability the identified loci explain. Searches for the claim’s wording, heritability, and explained genetic risk found no passage addressing that comparison; the indexed passages provide no page numbers. (LLM, conf=0.72)
- Partly supportedcites [2] Begum F, Ghosh D, Tseng GC, Feingold E. Comprehensive literature review and statistical considerations for GWAS meta-analysis. Nucleic Acids Res. 2012;40:3777–84. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says GWAS discoveries have been modest for many phenotypes and that typical effect sizes are small. It does not say what fraction of disease heritability the identified loci explain, so it supports the general idea of limited findings but not the claim’s specific heritability comparison. (LLM, conf=0.73)
- Supportedcites [3] Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76. source
The Challenges section states that genomewide association findings typically explain only a small proportion of disease heritability. The opening passage likewise says identified variants account for little heritability, supporting the claim's general wording. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Third, the same genetic variants often contribute to different final outcomes, depending on the environment and genetic background.”
§ Multi-omics approaches to disease > Introduction
What the sources say
- Could not verifycites [1] LaFramboise T. Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res. 2009;37:4181–93. sourceExperimental — accuracy not yet measured
Our copy of LaFramboise (2009) is a technical review of SNP array platforms, genotyping algorithms, LD/phasing, GWAS design, germline CNV and somatic LOH; no passage states that a single variant can yield different outcomes depending on environment or genetic background. Searches for 'penetrance/phenotype/variable expression', 'environmental factors/genetic background/modifier genes', 'pleiotropy/epistasis/gene-environment interaction' returned only the INTRODUCTION (variants encode diversity and disease susceptibility), the GWAS section (associated variant as putative predisposition allele), the ancestry/population-stratification section and the reference list — none of which make the claim's point. Since our copy neither states nor contradicts it, the attribution cannot be checked here. (LLM, conf=0.68)
- Partly supportedcites [2] Begum F, Ghosh D, Tseng GC, Feingold E. Comprehensive literature review and statistical considerations for GWAS meta-analysis. Nucleic Acids Res. 2012;40:3777–84. sourceExperimental — accuracy not yet measured
The GWAS META-ANALYSIS DATA AND METHODS section states that populations with different environmental backgrounds may have 'different genes ... relevant to the trait' (gene × environment interaction), and the Between-study heterogeneity / Case study sections note the same RNF212 variants act differently in males and females — so the environment-dependent modulation of genetic effects is in our copy. However, our copy nowhere says the SAME variants contribute to DIFFERENT final outcomes (pleiotropy), and it offers nothing on genetic background/epistasis as a modifier; the direction of its point is the reverse (different genes for one trait). The claim also states as a frequent fact ('often contribute') what the source hedges ('may be relevant', 'there may be gene × environment interaction'). (LLM, conf=0.65)
- Partly supportedcites [3] Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76. sourceExperimental — accuracy not yet measured
Our copy supports the first half of the claim: the Survey-of-Findings/Abstract section states that "genomewide association studies have identified loci that are shared by conditions previously thought to be unrelated (Table 2)," and Table 2 lists examples (CDKN2A/CDKN2B in coronary disease, type 2 diabetes and invasive melanoma; ORMDL3 in asthma and Crohn's disease; LRRK2 in Parkinson's disease and Crohn's disease; C10orf67 in sarcoidosis and celiac disease). What the source does NOT support is the conditional modifier "depending on the environment and genetic background": the Abstract and Glossary only say complex conditions arise from many genetic and environmental factors working together and list "interactions between genes or between genes and environmental factors" as candidate explanations for missing heritability, never as the reason a shared variant yields different outcomes. The word "often" is likewise not quantified in our copy. (LLM, conf=0.72)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Analyses of causal variants at GWAS loci focused originally on coding regions, but it has become clear that for many common diseases regulatory variation explains most of the risk burden [21].”
§ Multi-omics approaches to disease > Approaches to integrative analysis of multiple omics data > The genome first approach
What the sources say
- Could not verifycites [21] Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, et al. Epigenome-wide association study of body mass index and the adverse outcomes of adiposity. Nature. 2016;541:81–6. sourceExperimental — accuracy not yet measured
Our copy of Wahl et al. (2017) is an epigenome-wide association study of BMI; it reports that the 187 adiposity-related methylation loci are enriched in active chromatin/cis-regulatory regions (DNase hypersensitivity sites, H3K4me1, H3K27ac) and link to cis-gene expression (Abstract, functional genomics section), and that candidate genes implicate regulatory pathways linking adiposity to metabolic, cardiovascular, respiratory and neoplastic disease (Abstract). However, no passage states or supports the general proposition that for many common diseases regulatory variation explains most of the risk burden, nor contrasts early causal-variant work in coding regions with regulatory mechanisms. Searched: 'regulatory variation explains most of the risk burden', 'GWAS loci mostly non-coding regulatory variants rather than coding variants disease risk', 'most disease-associated variants lie in non-coding regulatory regions rather than protein-coding exons', 'common variants conferring disease risk act through gene regulation' — nothing on the claimed point, and nothing contrary to it. (LLM, conf=0.70)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“To identify differentially expressed genes between the cases and controls, the power provided by more samples is generally preferable to the increased accuracy provided by higher depth of sequencing.”
§ Multi-omics approaches to disease > Considerations for the design of omics studies > Downstream analysis, sample sizes, and power
What the sources say
- Partly supportedcites [7] Schurch NJ, Schofield P, Gierlinski M, Cole C, Sherstnev A, Singh V, et al. How many biological replicates are needed in an RNA-seq experiment and which differential expression tool should you use? RNA. 2016;22:839–51. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says increasing biological replicates usually makes RNA-seq results more robust, and the Discussion (page unavailable) recommends at least 12 clean replicates per condition when identifying most differentially expressed genes is important. The paper does not compare adding samples with increasing sequencing depth, so it does not establish the claimed preference between them. (LLM, conf=0.85)
- Partly supportedcites [8] Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, et al. A survey of best practices for RNA-seq data analysis. Genome Biol. 2016;17:13. sourceExperimental — accuracy not yet measured
Box 1 (Number of replicates; page unavailable) says that, after a certain sequencing depth, increasing the number of replicates is the better way to improve power. It does not establish that more samples are generally preferable: the same passage says deeper sequencing can improve power for low-expression genes and that the best trade-off depends on the experiment and budget. (LLM, conf=0.85)
- Partly supportedcites [9] Williams AG, Thomas S, Wyman SK, Holloway AK. RNA-seq data: challenges in and recommendations for experimental design and analysis. Curr Protoc Hum Genet. 2014;83:11.13.1–11.13.20. sourceExperimental — accuracy not yet measured
In “Simulated Differential Expression with Varying Numbers of Replicates and Sequence Depth” (page unavailable), the paper reports that more replicates can improve detection of differentially expressed genes, particularly when biological variance is high. It does not establish that adding samples is generally preferable to deeper sequencing: it also reports that substantial reductions in read depth sharply reduce detection power and recommends both a minimum number of replicates and a minimum sequencing depth. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In large studies, some technical artifacts cannot be avoided, and in these cases it is crucial to understand to what extent those artifacts limit our ability to draw conclusions from observations”
§ Multi-omics approaches to disease > Considerations for the design of omics studies > Downstream analysis, sample sizes, and power
What the sources say
- Could not verifycites [10] Gilad Y, Mizrahi-Man O. A reanalysis of mouse ENCODE comparative gene expression data. F1000Res. 2015;4:121. sourceExperimental — accuracy not yet measured
The Discussion identifies a sequencing batch effect and calls the Mouse ENCODE study design flawed, but does not say that technical artifacts are unavoidable in large studies. A search for unavoidable artifacts and large-study limitations found no passage making that point. (LLM, conf=0.72)
- Partly supportedcites [11] Peixoto L, Risso D, Poplawski SG, Wimmer ME, Speed TP, Wood MA, et al. How data analysis affects power, reproducibility and biological insight of RNA-seq studies in complex datasets. Nucleic Acids Res. 2015;43:7664–74. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says many sources of unwanted variation cannot be controlled in in-vivo brain gene-expression studies. The Discussion (page unavailable) also describes batch effects and artifacts when integrating RNA-seq data across laboratories. The paper does not establish that technical artifacts are unavoidable in large studies generally. (LLM, conf=0.82)
- Partly supportedcites [12] SEQC/MAQC-III Consortium. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nat Biotechnol. 2014;32:903–14. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies GC bias, sequence bias and non-specific signal as sources of unwanted or missed differential-expression calls in this multi-site study. It supports the presence and consequences of technical artifacts, but does not say that some artifacts cannot be avoided in large studies. (LLM, conf=0.78)
- Partly supportedcites [13] Hartley SW, Mullikin JC. QoRTs: a comprehensive toolset for quality control and data processing of RNA-Seq experiments. BMC Bioinformatics. 2015;16:224. sourceExperimental — accuracy not yet measured
The Background says RNA-Seq is prone to artifacts and that some biases are inherent; the Implementation section says such issues can call results into question. The paper does not establish that technical artifacts are unavoidable specifically in large studies, and it notes that many biases can be accounted for or corrected. The indexed passages provide section labels but no page numbers. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
49 more claims · 25 with their cited sources checked
Create a free account to see all 95 claims and to verify the 30 references still open.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 20
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In summary, by using new technologies, “omic” analysis and “big data”-integration of data from different platforms in a system biology approach-bias will be reduced and understanding of molecular mechanisms will be deepened (317).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [317]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, many of the multi-omic reviews are focussed on individual sub-topics.For example, designing studies (Haas et al., 2017;Hasin et al., 2017), setting up workflows (Kohl et al., 2014), choosing software tools (Misra et al., 2019) and evaluating overfitted performance (McCabe et al., 2020).”
From Using machine learning approaches for multi-omics data analysis: A review (2021) · cites this paper as Hasin et al., 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Multi-omics approaches to disease > Approaches to integrative analysis of multiple omics data > The genome first approach
“Claussnitzer and colleagues confirmed the roles of IRX2 and IRX5 using experimental manipulation in primary adipocytes and in mice.”
§ Multi-omics approaches to disease > Approaches to integrative analysis of multiple omics data > The genome first approach
“c Transcriptomics: this technique was used to identify which of the candidate genes are differentially expressed between the risk and normal haplotypes, identifying IRX3 and IRX5 as the likely downstream targets.”
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · cited 1×
“Several analytic tools have been developed for analyzing NGS data from targeted 16S or metagenomics analysis, such as QIIME (quantitative insights into microbial ecology) [167].”
MethodAn integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174 · cited 6×
“Thus, transcriptomics, employing either expression arrays or RNA-Seq (Box 1), has proven to be particularly useful for identifying causal genes at GWAS loci [16, 22–24].”
BackgroundInfluentialSudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 1×
“The UK biobank [15] collects samples and physiologic measures and follows 500,000 people with respect to their activity.”
BackgroundKlindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., & Glöckner, F. O. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks808 · Cited by 8,850
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 1×
“The microbiome has been shown to alter many aspects of host physiology, from obesity [86, 87] to cognition [88].”
BackgroundDNA methylation age of human tissues and cell types
Horvath, S. (2013) · Genome Biology · doi:10.1186/gb-2013-14-10-r115 · Cited by 7,075
Newman, M. (2010) · doi:10.1093/acprof:oso/9780199206650.001.0001 · Cited by 6,595
Cited by
Multivariable association discovery in population-scale meta-omics studies
Mallick, H., Rahnavard, A., McIver, L. J., Ma, S., Zhang, Y., Nguyen, L. H., Tickle, T. L., Weingart, G., Ren, B., Schwager, E. H., et al. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009442 · Cited by 2,596
“, nonbacterial, metagenomic, metatranscriptomic, metabolomic, and metaproteomic measurements assessed simultaneously in the same biological specimens [3,4].”
BackgroundMulti-omics Data Integration, Interpretation, and Its Application
Subramanian, I., Verma, S., Kumar, S., Jere, A., & Anamika, K. (2020) · Bioinformatics and Biology Insights · doi:10.1177/1177932219899051 · Cited by 1,609
Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets
Argelaguet, R., Velten, B., Arnol, D., Dietrich, S., Zenz, T., Marioni, J. C., Buettner, F., Huber, W., & Stegle, O. (2018) · Molecular Systems Biology · doi:10.15252/msb.20178124 · Cited by 1,510
mRNAs, proteins and the emerging principles of gene expression control
Buccitelli, C., & Selbach, M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0258-4 · Cited by 1,243
Using machine learning approaches for multi-omics data analysis: A review
Reel, P. S., Reel, S., Pearson, E., Trucco, E., & Jefferson, E. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107739 · Cited by 903
Metadata
- Authors
- Hasin, Y., Seldin, M., & Lusis, A.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Lusis, Aldons
- Venue
- Genome Biology
- Published
- 2017-05-05
- Volume
- 18
- Issue
- 1
- Pages
- 83-83
- ISSN
- 1465-6906 (ISSN-L)
- 1474-760X
- PMC
- PMC5418815
- OpenAlex
- W2611138580
- Semantic Scholar
- 7710b482b5956665598c0b8ca4c2cb37555287aa
- Cited by
- 2,953
- References
- 186
- Citations by year
- 2026: 650 · 2025: 467 · 2024: 395 · 2023: 328 · 2022: 315 · 2021: 317 · 2020: 225 · 2019: 152 · 2018: 84 · 2017: 18
- FWCI
- 12.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Genome biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (HL114437, HL28481)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Health, Environment, Cognitive Aging
- Keywords
- multi-omics integration, omics technologies, proteomics, metabolomics, transcriptomics, genomics, disease mechanisms
- MeSH terms
- Humans, Computational Biology, Genetic Predisposition to Disease, Genome-Wide Association Study, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-omics approaches to disease. https://app.cochat.ai/papers/10.1186/s13059-017-1215-1
- The paper
- Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. Genome Biology. https://doi.org/10.1186/s13059-017-1215-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.